Showing 3181-3190 of 5773 results for "".
- Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopiahttps://modernod.com/news/alcon-canada-launches-total30-multifocal-contact-lenses-for-reusable-lens-patients-with-presbyopia/2482093/Alcon announced the launch of TOTAL30 Multifocal in Canada, the first and only monthly water gradient multifocal contact lens. The new TOTAL30 Multifocal lens is designed to help digital device dryness by utilizing a proprietary water gradient technology to deliver nearly
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- New Long-Term Data for Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)https://modernod.com/news/new-long-term-data-for-genentechs-vabysmo-show-sustained-retinal-drying-and-vision-improvements-in-retinal-vein-occlusion-rvo/2482090/Genentech announced new 72-week data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). The data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48
- Théa Acquires Rights to KIO-301 for the Treatment of Inherited Retinal Diseases in $301 Million Dealhttps://modernod.com/news/thea-acquires-rights-to-kio-301-for-the-treatment-of-inherited-retinal-diseases-in-301-million-deal/2482089/Kiora Pharmaceuticals announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister company of Laboratoires Théa under with Kiora granted Théa exclusive worldwide development and commercialization rig
- EuroEyes Group Wins SMILE Refractive Laser Eye Surgery Awardhttps://modernod.com/news/euroeyes-group-wins-smile-refractive-laser-eye-surgery-award/2482087/LEC London announced that its parent company EuroEyes Clinic Group, has won the SMILE Laser Operations Award for conducting the highest number of SMILE (Small Incision Lenticule Extraction) laser operations in Europe last year (2023). EuroEyes performed a total of 9,550 SMILE operations
- Ascendis Pharma Forms New Ophthalmology Company Eyconishttps://modernod.com/news/ascendis-pharma-forms-new-ophthalmology-company-eyconis/2482086/Ascendis Pharma A/S announced the formation and launch of Eyconis, a company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. The new company was developed with Frazier Life Sciences, as well as an investor syndicate that includes RA Capital Man
- Mireca Medicines Awarded Nearly $1 Million from the Foundation Fighting Blindness to Develop Treatments for IRDshttps://modernod.com/news/mireca-medicines-awarded-nearly-1-million-from-the-foundation-fighting-blindness-to-develop-treatments-for-inherited-retinal-diseases/2482085/Mireca Medicines announced it has received a $989,000 'Translational Research Acceleration Program Award' from Foundation Fighting Blindness that will permit the company to further advance the preclinical development of its lead product MM238. In a news
- Apellis Receives Negative Opinion for Pegcetacoplan for GA in the EU; Plans to Seek Re-Examination of Applicationhttps://modernod.com/news/apellis-receives-negative-opinion-for-pegcetacoplan-for-ga-in-the-eu-plans-to-seek-re-examination-of-application/2482083/Apellis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to
- Iridex Enrolls First Patient in MicroPulse TLT Study in Collaboration with Imperial College Healthcare NHS Trusthttps://modernod.com/news/iridex-enrolls-first-patient-in-micropulse-tlt-study-in-collaboration-with-imperial-college-healthcare-nhs-trust/2482081/Iridex and Imperial College Healthcare NHS Trust in London announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse Transscleral Laser Therapy (TLT) using the Iridex Cyclo G6 Laser and th
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc